12:00 AM
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BBI608: Phase III discontinued

Dainippon discontinued the double-blind, placebo-controlled, international Phase III CO.23 trial evaluating twice-daily 480 mg BBI608 plus best supportive care (BSC) to treat colorectal cancer after a futility analysis based on DCR of the first 97 patients met the protocol-defined criteria for...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >